<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
July 25, 1997
-----------------------------
Date of Report
(Date of earliest event reported)
ELECTROPHARMACOLOGY, INC.
-------------------------
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-25828 95-4315412
- ------------------------------- ------------------------ ------------------
(State or other Jurisdiction of (Commission File Number) (I.R.S. Employer
Incorporation) Identification No.)
2301 N.W. 33RD COURT, SUITE 102
POMPANO BEACH, FLORIDA 33069
- ------------------------------- ----------
(Address of Principal Executive (Zip Code)
Offices)
(954) 975-9818
----------------------------------------------------
(Registrant's telephone number, including area code)
<PAGE>
ITEM 5. OTHER EVENTS.
Electropharmacology, Inc. ("Registrant") announced on July 24, 1997 that it
requested a review of the Nasdaq staff's determination of delisting of its stock
from the Nasdaq Small Cap Market. Registrant expects that the Nasdaq hearing
will be scheduled in due course when Registrant will present its strategy to
achieve compliance. In the interim, Registrant has been advised that its stock
will remain listed on the Nasdaq stock market pending the outcome of the
hearing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Electropharmacology, Inc.
By: /s/ ARUP SEN
------------------------------------------
Arup Sen
President and Chief Executive Officer
July 25, 1997
-2-
